» Articles » PMID: 37737972

Sertoli Cell-Conditioned Medium Induces Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells to Male Germ-Like Cells in Busulfan-Induced Azoospermic Mouse Model

Overview
Journal Reprod Sci
Publisher Springer
Date 2023 Sep 22
PMID 37737972
Authors
Affiliations
Soon will be listed here.
Abstract

Non-obstructive azoospermia is a severe form of male infertility, with limited effective treatments. Bone marrow mesenchymal stem cells (BMSCs) can differentiate to different cell lines; therefore, transplantation of these cells is used for treatment of several diseases. Since these cells require induction factors to differentiate into germ cells, we co-transplanted bone marrow stem cells (BMSCs) with Sertoli cell-conditioned medium (SCCM) into the testis of azoospermic mice. This study was carried out in two sections, in vitro and in vivo. For in vitro study, differentiating factors (c-kit and ID4) were examined after 15 days of co-culture of bone marrow cells with Sertoli cell-conditioned medium, while for in vivo study, the azoospermia model was first created by intraperitoneal administration of a single-dose busulfan (40 mg/kg) followed by single-dose CdCl (2 mg/kg) after 4 weeks. Mice were divided into 4 groups including control (azoospermia), BMSC, SCCM, and BMSC + SCCM. Eight weeks after transplantation, samples were assessed for proliferation and differentiation via the expression level of MVH, ID4, SCP3, Tp1, Tp2, and Prm1 differentiation markers. The results showed that BMSC co-cultured with SCCM in vitro differentiated BMSC to germ-like cells. Similarly, in vivo studies revealed a higher level of BMSC differentiation into germ-like cells with significant higher expression of differentiation markers in transplanted groups compared to the control. This study confirmed the role of SCCM as an inductive factor for BMSC differentiation to germ cells both in vivo and in vitro conditions.

Citing Articles

Enhancing Spermatogenesis in Non-obstructive Azoospermia Through Mesenchymal Stem Cell Therapy22.

Margiana R Curr Stem Cell Res Ther. 2024; 19(11):1429-1441.

PMID: 38243988 DOI: 10.2174/011574888X283311231226081845.

References
1.
Duca Y, Calogero A, Cannarella R, Condorelli R, La Vignera S . Current and emerging medical therapeutic agents for idiopathic male infertility. Expert Opin Pharmacother. 2018; 20(1):55-67. DOI: 10.1080/14656566.2018.1543405. View

2.
Punab M, Poolamets O, Paju P, Vihljajev V, Pomm K, Ladva R . Causes of male infertility: a 9-year prospective monocentre study on 1737 patients with reduced total sperm counts. Hum Reprod. 2016; 32(1):18-31. PMC: 5165077. DOI: 10.1093/humrep/dew284. View

3.
Jarvi K, Lo K, Fischer A, Grantmyre J, Zini A, Chow V . CUA Guideline: The workup of azoospermic males. Can Urol Assoc J. 2010; 4(3):163-7. PMC: 2874589. DOI: 10.5489/cuaj.10050. View

4.
Esteves S . Clinical management of infertile men with nonobstructive azoospermia. Asian J Androl. 2015; 17(3):459-70. PMC: 4430952. DOI: 10.4103/1008-682X.148719. View

5.
Vij S, Sabanegh Jr E, Agarwal A . Biological therapy for non-obstructive azoospermia. Expert Opin Biol Ther. 2017; 18(1):19-23. DOI: 10.1080/14712598.2018.1380622. View